HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers
  • About
    • Mission
    • Team
  • Our Science
    • Overview
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • Patients & Caregivers
  • News & Publications
  • Contact
  • Careers

Publication Topic: HiberCell's Publications

Novel GCN2 Modulator HC-7366 Inhibits Myeloid-derived Suppressor Cells and Reduces Pulmonary Metastases

SITC 2022 GCN2 Poster 1327_J_Drees PDF

Perk Inhibitor HC-5404 Demonstrates Immune-activation and Anti-tumor Efficacy in Combination with Anti-PD1 Immune Checkpoint Inhibitor Antibody

SITC 2022 PERK Poster_P884 Chan PDF

Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors

Cancer immunotherapy via myeloid signaling pathway co-activation (Wattenberg et al. AACR Pancreatic Cancer 2022)

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

PERK inhibition blocks metastasis initiation by limiting UPR-dependent survival of dormant disseminated cancer cells

Quantum processor-inspired machine learning in the biomedical sciences

A novel, phase 2 study in second line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

Response and clinical benefit assessment of the combination of the dectin-1 agonist Imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

Posts navigation

Older posts
HiberCell
  • About
    • Mission
    • Team
  • Our Science
    • Our Science
    • Odetiglucan
    • HC-5404
    • HC-7366
  • Pipeline
  • News & Publications
  • Contact
  • Careers
Linked In

© 2023 Hibercell Inc |
Privacy Policy |
Terms & Conditions |
Expanded Access